Dianthus Therapeutics, Inc. (DNTH)
(Delayed Data from NSDQ)
$21.50 USD
+0.91 (4.42%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $21.43 -0.07 (-0.33%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Dianthus Therapeutics, Inc.'s return on equity, or ROE, is -29.26% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.55%. While this shows that DNTH has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
DNTH 21.50 +0.91(4.42%)
Will DNTH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DNTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNTH
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates
DNTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock?
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates
Other News for DNTH
Commit To Buy Dianthus Therapeutics At $12.50, Earn 26.6% Annualized Using Options
Dianthus (DNTH) Price Target Raised by Guggenheim Ahead of Key Trial
Dianthus price target raised by $8 at Guggenheim, here's why
Dianthus initiated with bullish view at William Blair, here's why
Dianthus Therapeutics (DNTH) Receives Outperform Rating by William Blair | DNTH Stock News